SMITH & NEPHEW PLC (SNN) Form 6-K — Aug 4, 2026
Smith+Nephew reported first-half 2026 revenue of $3.1 billion, with underlying growth of 2.3% aided by foreign exchange tailwinds, while trading profit rose 8.1% to $566 million due to efficiency savings. Despite the profit growth, the company faced headwinds in US Orthopaedics and Advanced Wound Bioactives, leading to a reduction in full-year revenue guidance from approximately 6% to around 4%. Management maintained its guidance for trading profit growth of around 8%, free cash flow of $800 million, and double-digit adjusted ROIC, projecting a second-half revenue acceleration to 5.0%-5.5%.
Key figures
- Eps
- 35.6
- Revenue
- 3097
- Guidance
- Full year revenue growth around 4% (previously 6%); trading profit growth around 8%; free cash flow around $800 million.
- Net Income
- 303
- Total Debt
- 3588
- Revenue Yoy
- 2.3%
- Cash Position
- 754
- Free Cash Flow
- 231
- Adjusted EPSA
- 47.7
- Interim Dividend
- 15.6 cents
- Share Buyback Settled
- 216
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.